KRBPQ — Kiromic Biopharma Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
Brief: Kiromic BioPharma Reports Favorable Safety, Tolerability, And Early Efficacy From Third Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Announces First Patient Dosed In Phase 1 Study Evaluating Deltacel
Brief: Kiromic Biopharma Common Stock To Begin Trading On The Otc Pink Sheets On September 14
Brief: Kiromic Biopharma Appoints Brian Hungerford As Interim CFO
Brief: Kiromic BiopharmaOn May 11, Nasdaq Hearings Panel Granted Request For Extension Until Sept 11, For Co To Comply With Stockholders’ Equity Requirement
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Marker Therapeutics, KBR
Kiromic BioPharma rises on FDA nod for lung cancer therapy trial
Brief: Kiromic Biopharma Announces FDA Authorization Of IND To Initiate Phase 1 Clinical Trial Evaluating Deltacel In Non-Small Cell Lung Cancer
Kiromic BioPharma up on filing application to start lung cancer therapy trial
Brief: Kiromic Biopharma Announces Reverse Stock Split
Brief: Kiromic Biopharma Reports Favorable Deltacel Preclinical Pharmacology Results
Brief: Kiromic Biopharma Says CFO Dan Clark Notified Of His Decision To Resign
Brief: Kiromic Biopharma Inc - On Dec 12, Co Amended And Restated 25% Senior Secured Convertible Promissory Note Dated October 21, 2022